Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

Award Number: R42AI122403
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/05/2016
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease - PROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates of 50-90%. The 2014-2015 epidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for development of therapeutics. Among the five ebolavirus species, the Zaire and Sudan subtypes (EBOV and SUDV, respectively) are the most pathogenic and both have resulted in recurring outbreaks. Furthermore, Bundibugyo virus (BDBV) has also caused two sizable outbreaks over the past decade. However, current filovirus antibody therapies are narrowly specific to Zaire Ebola virus and ineffective against SUDV and BDBV. The goal of this proposal is to develop a bispecific antibody (Bis-mAb) therapeutic with broad protection against all ebolaviruses that have caused human disease. In the Phase I of this STTR we created a prototype Bis-mAb that combines the antigen binding variable domains of a non-neutralizing pan-ebolavirus antibody with an antibody against a cryptic epitope within the receptor binding site of ebolavirus glycoprotein that becomes exposed only within the endosomes. The Bis- mAb colocalizes to the endosomes with the virus where the antibody against the cryptic epitope becomes effective due to proteolytic cleavage of the glycoprotein by cysteine cathepsins. This approach enabled us to generate a “Trojan Horse” that co-opts the virus to deliver a lethal weapon into the endosomes leading to effective virus neutralization. This prototypic pan-ebolavirus Bis-mAb (FVM09~MR72) potently neutralized all five ebolavirus species while a cocktail of the parental IgGs was ineffective. In mice, FVM09~MR72 protected against lethal challenge with EBOV and SUDV, the most divergent ebolaviruses. In the Phase II project, we propose to demonstrate protective efficacy of the product in nonhuman primates and ferrets to achieve a critical milestone that would justify clinical development. In Aim 1 we will produce the Bis-mAb in CHO cells by transient transfection at scale required for large animal studies. Stable cell lines will be also generated for use in future manufacturing of the product. In Aim 2, we will evaluate the pharmacokinetics of the Bis-mAb and conduct proof of principal efficacy against SUDV and EBOV in NHPs and against BDBV in ferrets. This work represents a partnership between academic (Einstein) and commercial (Integrated BioTherapeutics) entities to develop a cross-neutralizing therapeutic Bis-mAb. The approach leverages proprietary antibodies, technology platforms, and complementary expertise from both partners.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2018	INTEGRATED BIOTHERAPEUTICS, LLC	4 RESEARCH CT STE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	3	11/23/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = -$123,788 )
2022	2018	INTEGRATED BIOTHERAPEUTICS INC	4 RESEARCH CT	POTOMAC	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	3	1/28/2022	NON-COMPETING CONTINUATION	-$123,788
														Subtotal = -$123,788

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	3	6/15/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $1,000,088 )
2018	2018	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	001	3	6/15/2018	NON-COMPETING CONTINUATION	$1,000,000
2018	2017	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	3/22/2018	COMPETING CONTINUATION	$88
														Subtotal = $1,000,088

Issue Date FY: 2017 ( Subtotal = $861,259 )
2017	2017	INTEGRATED BIOTHERAPEUTICS, INC.	4 RESEARCH COURT, SUITE 300	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	2	6/23/2017	COMPETING CONTINUATION	$861,259
														Subtotal = $861,259

Grand Total All Awards = $1,737,559

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

Award Number: R42AI122403

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/05/2016

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer